Lataa...
The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study)
BACKGROUND: Tiotropium + olodaterol has demonstrated improvements beyond lung function benefits in a large Phase III clinical program as a once-daily maintenance treatment for COPD and may be a potential option for the initiation of maintenance treatment in COPD. Despite guideline recommendations th...
Tallennettuna:
| Julkaisussa: | Int J Chron Obstruct Pulmon Dis |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4745834/ https://ncbi.nlm.nih.gov/pubmed/26893551 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S95055 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|